Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness

Juillerat, Pascal; Pittet, Valérie; Vader, John-Paul; Burnand, Bernard; Gonvers, Jean-Jacques; de Saussure, Philippe; Mottet, Christian; Seibold, Frank; Rogler, Gerhard; Sagmeister, Markus; Felley, Christian; Michetti, Pierre; Froehlich, Florian; Swiss Cohort Study, (2010). Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness. European journal of gastroenterology & hepatology, 22(11), pp. 1352-7. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1097/MEG.0b013e32833eaa8a

Full text not available from this repository. (Request a copy)

Antitumor necrosis factor a agents have significantly improved the management of Crohn's disease (CD), but not all patients benefit from this therapy. We used data from the Swiss Inflammatory Bowel Disease Cohort Study and predefined appropriateness criteria to examine the appropriateness of use of infliximab (IFX) in CD patients.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology

UniBE Contributor:

Seibold, Frank Werner

ISSN:

0954-691X

Publisher:

Lippincott Williams & Wilkins

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:10

Last Modified:

04 May 2014 23:05

Publisher DOI:

10.1097/MEG.0b013e32833eaa8a

PubMed ID:

20964261

Web of Science ID:

000282984600012

URI:

https://boris.unibe.ch/id/eprint/1488 (FactScience: 203171)

Actions (login required)

Edit item Edit item
Provide Feedback